U.S. Food and Drug Administration (FDA) Has Accepted the New Drug Application (NDA) for Ensartinib

MIAMI--(BUSINESS WIRE) March 13, 2024 --Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ensartinib, an Anaplastic...

https://www.drugs.com/nda/ensartinib_240313.html

Source: Drugs.com - New Drug Applications - March 13, 2024 Category: Drugs & Pharmacology Source Type: news

More News: Cancer & Oncology | Drugs & Pharmacology | Food and Drug Administration (FDA) | New Drug Applications